United States SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

CCI	TTT.	'T	TIT	T	12	
SC:	пс	IJ	UL	æ	TO	U

Under the Securities Exchange Act of 1934 (Amendment No. 1)*

Black Diamond Therapeutics, Inc.

(Name of Issuer)

Common Stock (Title of Class of Securities)

09203E105 (CUSIP Number)

December 31, 2021 (Date of Event Which Requires Filing This Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

☐ Rule 13d-1(b)

☐ Rule 13d-1(c)

☐ Rule 13d-1(d)

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CUSIP No. **09203E105**

1.	Names of Reporting Persons					
	BB Bio					
2.	Check the (a) ⊠		propriate Box if a Member of a Group (See Instructions)			
	(a) 🖾 (נט) נ				
3.	SEC Use	Onl	y			
4.	Citizenship or Place of Organization					
	Switzerland					
Number of Shares		5.	Sole Voting Power			
			0			
		6.	Shared Voting Power			
	neficially		3,440,000			
	Owned by Each		Sole Dispositive Power			
	Reporting					
	with:	8.	O Shared Dispositive Power			
	8. Snared Dispositive Power					
	3,440,000					
9.	9. Aggregate Amount Beneficially Owned by Each Reporting Person					
	3,440,000					
10.	D. Check if the Aggregate Amount in Row (9) Excludes Certain Shares □					
11.	. Percent of Class Represented by amount in Row (9)					
	9.5%					
12.		Repo	rting Person (See Instructions)			
	HC,CO					

CUSIP No. 09203E105

1.	. Names of Reporting Persons					
	Biotech Growth N.V.					
	I.R.S. Id	lent	ification Nos. of above persons (entities only):			
	N/A					
2.	2. Check the Appropriate Box if a Member of a Group (See Instructions)(a) □					
3.	3. SEC Use Only					
4.	Citizenship or Place of Organization					
	Curacao					
		5.	Sole Voting Power			
			0			
	ımber of Shares	6.	Shared Voting Power			
Be	neficially					
Owned by 3,440,000						
	Each 7. Sole Dispositive Power Reporting					
Person 0		0				
with: 8. Shared Dispositive Power		Shared Dispositive Power				
	3,440,000					
9.	9. Aggregate Amount Beneficially Owned by Each Reporting Person					
	3,440,000					
10.						
11.	1. Percent of Class Represented by amount in Row (9)					
	9.5%					
12.						
	CO					

Item 1

- 1(a) Name of Issuer: Black Diamond Therapeutics, Inc.
- 1(b) Address of Issuer's Principal Executive Offices:

One Main Street, 10th Floor, Cambridge, MA 02142

Item 2

- 2(a) Name of Person Filing: <u>BB Biotech AG ("BB Biotech") on behalf of its wholly-owned subsidiary, Biotech Growth N.V. ("Biotech Growth")</u>
 - 2(b) Address of Principal Business Office or, if none, Residence:

BB Biotech AG: Schwertstrasse 6, CH-8200 Schaffhausen, Switzerland

Biotech Growth N.V.: Ara Hill Top Building, Unit A-5, Pletterijweg Oost 1, Curaçao

2(c) Citizenship: BB Biotech AG: Switzerland

Biotech Growth N.V.: Curacao

- 2(d) Title of Class of Securities Common Stock, par value \$0.0001 per share
- 2(e) CUSIP Number <u>09203E105</u>

Item 4. Ownership

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

- (a) Amount beneficially owned: 3,440,000
- (b) Percent of class: 9.5%
- (c) Number of shares as to which the person has:
- (i) Sole power to vote or to direct the vote $\underline{0}$
- (ii) Shared power to vote or to direct the vote 3,440,000
- (iii) Sole power to dispose or to direct the disposition of $\underline{0}$
- (iv) Shared power to dispose or to direct the disposition of 3,440,000
- Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company or Control Person.

This statement is filed jointly by BB Biotech and Biotech Growth, Biotech Growth is a wholly-owned subsidiary of BB Biotech.

Item 10. Certification

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURES

After reasonable inquiry and the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

BB Biotech AG

Date: February 9, 2022	By:	/s/ Martin Gubler
		Signatory Authority
	Name:	Martin Gubler
	Title:	Signatory Authority
Date: <u>February 9, 2022</u>	Ву:	/s/ Ivo Betschart
		Signatory Authority
	Name:	Ivo Betschart
	Title:	Signatory Authority
Biotech Growth N.V.		
Date: <u>February 9, 2022</u>	By:	/s/ Jan Bootsma
		Signatory Authority
	Name:	Jan Bootsma
	Title:	Signatory Authority
Date: <u>February 9, 2022</u>	Ву:	/s/ Hugo van Neutegem
		Signatory Authority
	Name:	Hugo van Neutegem
	Title:	Signatory Authority

5 of 6

Exhibit Index

Exhibit A: Agreement by and between BB Biotech AG and Biotech Growth N.V. with respect to the filing of this disclosure statement.*

* Previously filed as an exhibit to BB Biotech AG and Biotech Growth N.V.'s Schedule 13G filed with the Securities and Exchange Commission on February 11, 2021.